RIPK1,

Xin Yu1,2, Dong Lu3, Xiaoli Qi1,2

  • 1The Verna and Marrs McLean Department of Biochemistry and Molecular Pharmacology, Baylor College of Medicine, Houston, TX, USA.

Nature communications
|December 16, 2024
PubMed
概括

我们开发了LD4172,一种新的PROTAC降解剂,准受体相互作用蛋白激酶1 (RIPK1). 这种RIPK1降解剂通过触发细胞死亡和改善抗瘤免疫反应来增强癌症免疫疗法.